ライフサイエンスコーパス: Plasmodium yoelii

1 P) identified in the murine malaria parasite Plasmodium yoelii.

2 1 (yMSP1(19)) of the murine malaria parasite Plasmodium yoelii.

3 onocytogenes and the rodent malaria parasite Plasmodium yoelii.

4 ated apicomplexans Plasmodium falciparum and Plasmodium yoelii.

5 -3 fatty acids survive infection with lethal Plasmodium yoelii.

6 ce to pure artemisinin in the rodent malaria Plasmodium yoelii.

7 d gene-targeting techniques to delete PAT in Plasmodium yoelii.

8 rotein (SSP3) in the rodent malaria parasite Plasmodium yoelii.

9 cts on Plasmodium liver stages in vivo using Plasmodium yoelii.

10 imaging (BLI) of the rodent malaria parasite Plasmodium yoelii.

11 tic stages in vivo using the rodent parasite Plasmodium yoelii.

12 of this family exist in the rodent parasite Plasmodium yoelii.

13 ANKA, and by spleen macrophages and DCs from Plasmodium yoelii 17NXL-infected and P. berghei ANKA-inf

14 Here, we test chemically attenuated Plasmodium yoelii 17X and demonstrate significant protec

15 ited in mice infected by the malaria species Plasmodium yoelii 17X NL.

16 ates in response to infection with nonlethal Plasmodium yoelii 17X.

17 coinfected with M. tuberculosis CDC1551 and Plasmodium yoelii 17XL had a lower peak parasitemia and

18 We show that co-infection of mice with Plasmodium yoelii 17XNL (Py17XNL) and Salmonella enteric

19 CD47 on the growth and survival of nonlethal Plasmodium yoelii 17XNL (PyNL) malaria in C57BL/6 mice.

20 semisynchronous, Plasmodium berghei ANKA- or Plasmodium yoelii 17XNL-parasitized red blood cells (pRB

21 on a C57BL/6 background were challenged with Plasmodium yoelii (17XNL strain) sporozoites, and then l

22 e structure and amino acid homology with the Plasmodium yoelii 235-kDa rhoptry protein family, which

23 ls is strongly reduced in mice infected with Plasmodium yoelii, a rodent malaria model.

24 nctions in intact erythrocytes infected with Plasmodium yoelii, a rodent malaria parasite.

25 f biosynthetic machinery to synthesize PABA, Plasmodium yoelii, a rodent malaria species, requires ex

26 Two candidate Plasmodium yoelii adhesion proteins are apical membrane

27 ressing the circumsporozoite (CS) protein of Plasmodium yoelii (AdPyCS), followed by a booster with a

28 the microbial pathogens Candida albicans and Plasmodium yoelii, an accepted experimental malaria mode

29 imensional structure of the TRAP A-domain of Plasmodium yoelii and located regions surrounding the MI

30 Rodent malaria species Plasmodium yoelii and P. chabaudi have been widely used

31 to be increased in vivo and in vitro during Plasmodium yoelii and P. falciparum intrahepatic develop

32 Studies with Plasmodium yoelii and P. falciparum show that the C-term

33 cytic stages of the rodent malaria parasites Plasmodium yoelii and Plasmodium berghei.

34 liver stages of the rodent malaria parasite Plasmodium yoelii and studied the early events in the de

35 The 235-kDa family of rhoptry proteins in Plasmodium yoelii and the two reticulocyte binding prote

36 ropoiesis are features of malarial anemia in Plasmodium yoelii- and Plasmodium berghei ANKA-infected

37 Rodent models of malaria, commonly Plasmodium yoelii, are frequently used for studies of ma

38 tope of the circumsporozoite protein (CS) of Plasmodium yoelii between 17D nonstructural proteins NS2

39 surface protein-1 protein vaccines against a Plasmodium yoelii blood-stage challenge.

40 Targeted deletion of SAP1 in Plasmodium yoelii caused the depletion of a number of se

41 rovided complete protection against a lethal Plasmodium yoelii challenge in mice.

42 We have reported a Plasmodium yoelii chimeric multistage recombinant protei

43 by inserting a B cell epitope derived from a Plasmodium yoelii circumsporozoite (CS) protein (referre

44 tudies using vaccine constructs based on the Plasmodium yoelii circumsporozoite protein (CSP) and P.

45 tion with a naked DNA plasmid expressing the Plasmodium yoelii circumsporozoite protein (pPyCSP) prot

46 Previous studies indicated that the Plasmodium yoelii circumsporozoite protein (PyCSP) 57-70

47 iming with DNA vaccine plasmids encoding the Plasmodium yoelii circumsporozoite protein (PyCSP) and m

48 first immunized as neonates (7 days) with a Plasmodium yoelii circumsporozoite protein (PyCSP) DNA v

49 induce protective CTL responses against the Plasmodium yoelii circumsporozoite protein (PyCSP), BALB

50 lity complex-restricted 9-mer epitope of the Plasmodium yoelii circumsporozoite protein or the nucleo

51 t immunization with plasmid DNA encoding the plasmodium yoelii circumsporozoite protein protected one

52 -) mice infected with a non-lethal strain of Plasmodium yoelii Compared with Cd36(-/-) mice, WT mice

53 Vaccination of mice with yeast-secreted Plasmodium yoelii-derived 19-kilodalton merozoite surfac

54 specific for the circumsporozoite protein of Plasmodium yoelii develop a severely impaired memory res

55 its a dose-dependent blocking effect against Plasmodium yoelii development in An. stephensi.

56 Infection of mice with Plasmodium yoelii elicited infiltration of inflammatory

57 We find that during the acute phases of Plasmodium yoelii erythrocyte stage infection, APC upreg

58 that experimental immunization of mice with Plasmodium yoelii fabb/f(-) (Pyfabb/f(-)), a genetically

59 ve immunity induced by immunization with the Plasmodium yoelii fabb/f(-) genetically attenuated paras

60 We disrupted the Plasmodium yoelii gene encoding high mobility group nucl

61 etion of SAP1 in the rodent malaria parasite Plasmodium yoelii generated mutant parasites that traver

62 protracted sterile protection conferred by a Plasmodium yoelii genetically attenuated parasite (PyGAP

63 The sequencing of the Plasmodium yoelii genome, a model rodent malaria parasit

64 Our research shows that apicoplast-targeted Plasmodium yoelii glycerol 3-phosphate dehydrogenase and

65 er stages in the murine malaria model system Plasmodium yoelii has been cumbersome and requires termi

66 ce with sporozoites of Plasmodium berghei or Plasmodium yoelii has been used extensively to evaluate

67 s a vaccine to induce protective immunity to Plasmodium yoelii in mice and to Plasmodium falciparum i

68 l prophylactic antimalarial activity against Plasmodium yoelii in mouse by oral administration.

69 alarial activity against multidrug-resistant Plasmodium yoelii in Swiss mice by oral route.

70 ty by oral route against multidrug-resistant Plasmodium yoelii in Swiss mice.

71 accinia virus protein 14K (A27) to the CS of Plasmodium yoelii, induces strong effector memory CD8(+)

72 that specific ablation of Foxp3(+) Tregs in Plasmodium yoelii-infected DEREG-BALB/c mice leads to an

73 e inhibitors for their capacity to eliminate Plasmodium yoelii-infected hepatocytes.

74 n vitro and in vivo and cleared malaria from Plasmodium yoelii-infected mice, resulting in 100% mice

75 tested in vivo in Plasmodium berghei- and/or Plasmodium yoelii-infected mice.

76 D8(+) T-cell-derived IFN-gamma production in Plasmodium yoelii-infected mice.

77 d expression of effector cytokines following Plasmodium yoelii infection and are therefore more resis

78 at it inhibits PfPSD activity and eliminates Plasmodium yoelii infection in mice.

79 rentiates into mature B cells in response to Plasmodium yoelii infection in mice.

80 to bites from uninfected mosquitoes prior to Plasmodium yoelii infection influences the local and sys

81 In our experiments, Plasmodium yoelii infection led to a reduced CD8(+) T ce

82 uggest that phenotypic changes in DCs during Plasmodium yoelii infection represent a mechanism of con

83 During a Plasmodium yoelii infection, these regulatory CD11clowCD

84 c mice are altered during the liver stage of Plasmodium yoelii infection.

85 rtments throughout the course of blood-stage Plasmodium yoelii infection.

86 genomics protein PY01515 (PDB ID 2aqw) from Plasmodium yoelii, it is shown that the putative annotat

87 at identifies host kinases, which facilitate Plasmodium yoelii liver stage infection.

88 ish between lethal and nonlethal blood stage Plasmodium yoelii malaria infections.

89 ra from mice immunized and protected against Plasmodium yoelii malaria, we identified a novel blood-s

90 was shown previously to protect mice against Plasmodium yoelii malaria.

91 Immunization with Plasmodium yoelii merozoite surface protein (PyMSP)-8 pr

92 specific for the C-terminal 19-kDa region of Plasmodium yoelii merozoite surface protein 1 (MSP119),

93 the full-length form and C and N termini of Plasmodium yoelii merozoite surface protein 1 provided p

94 nstrated that, when the C terminus (PyC2) of Plasmodium yoelii merozoite surface protein-1 (MSP-1), a

95 Immunization with Plasmodium yoelii merozoite surface protein-8 (PyMSP-8)

96 n against sporozoite challenge in the rodent Plasmodium yoelii model.

97 regions of MSP1 can also induce protection, Plasmodium yoelii MSP1 was divided into four separate re

98 We used the Plasmodium yoelii murine model to study the potential ro

99 The Plasmodium yoelii murine model was used to test several

100 Previously, using the Plasmodium yoelii murine model, we fused P. yoelii MSP1(

101 Based on proof-of-concept studies in the Plasmodium yoelii murine model, we produced a chimeric v

102 responses to infections with two strains of Plasmodium yoelii (N67 and N67C) and discovered differen

103 alarial activity against multidrug-resistant Plasmodium yoelii nigeriensis in Swiss mice.

104 C57BL/6 mice infected with Plasmodium yoelii nigeriensis N67C display high levels o

105 Typhimurium challenge in mice infected with Plasmodium yoelii nigeriensis.

106 in knockout (beta2M-/-) mice with irradiated Plasmodium yoelii or P. berghei sporozoites.

107 Here, we show that the Plasmodium yoelii orthologs of four Plasmodium falciparu

108 identity with its Plasmodium falciparum and Plasmodium yoelii orthologs, respectively.

109 ws between 19% (Plasmodium berghei) and 26% (Plasmodium yoelii) overall identity to the different Pla

110 Here, we generated p52/p36-deficient Plasmodium yoelii parasites by the simultaneous deletion

111 Infection of mice with strains of Plasmodium yoelii parasites can result in different path

112 vector platform are highly effective against Plasmodium yoelii parasites in mice and against Plasmodi

113 during infection with virulent and avirulent Plasmodium yoelii parasites in relatively susceptible an

114 etion of the E1 alpha or E3 subunit genes of Plasmodium yoelii PDH caused no defect in blood stage de

115 Epitope-tagged Plasmodium yoelii PlasMei2 was expressed only during liv

116 that BALB/cByJ mice are more susceptible to Plasmodium yoelii preerythrocytic infection than BALB/cJ

117 recently reported the discovery of a 17-kDa Plasmodium yoelii protein expressed in infected hepatocy

118 our reported approach of developing chimeric Plasmodium yoelii proteins to enhance protective efficac

119 Using the murine parasite Plasmodium yoelii (Py) as a model for malaria vaccine de

120 ion of BALB/c mice with a plasmid expressing Plasmodium yoelii (Py) circumsporozoite protein (CSP) in

121 Green fluorescent protein-tagged Plasmodium yoelii (PyGFP) was used to efficiently isolat

122 ne encoding the 60-kDa heat shock protein of Plasmodium yoelii (PyHsp60) was cloned into the VR1012 a

123 parasites (Plasmodium falciparum (PfMIF) and Plasmodium yoelii (PyMIF)) non-competitively in a revers

124 inia viruses expressing specific antigens of Plasmodium yoelii resulted in a dramatic protective immu

125 ith the genomes of Plasmodium falciparum and Plasmodium yoelii revealed a conserved core of 4500 Plas

126 s study, mice infected with malaria-inducing Plasmodium yoelii revealed that chloroquine treatment co

127 d deletions of the UIS3 and UIS4 loci in the Plasmodium yoelii rodent malaria model (Pyuis3[-] and Py

128 mmunogenicity and efficacy studies using the Plasmodium yoelii rodent model, we tested the ability of

129 ppression subtractive hybridization (SSH) of Plasmodium yoelii salivary gland sporozoites versus mero

130 reviously, we described the isolation of the Plasmodium yoelii sequence-related molecules P. yoelii M

131 Here we show that dendritic cells presenting Plasmodium yoelii sporozoite antigens are able to activa

132 or immune serum with a luciferase-expressing Plasmodium yoelii sporozoite challenge to assess Ab-medi

133 tibody against the 100-kDa protein inhibited Plasmodium yoelii sporozoite invasion of salivary glands

134 The Plasmodium yoelii sporozoite surface protein 2 (PySSP2)

135 18-amino-acid synthetic linear peptide from Plasmodium yoelii sporozoite surface protein 2 (SSP2) in

136 Here, using mice singly immunized with Plasmodium yoelii sporozoites and high-throughput screen

137 antigen 1 to 2 days prior to challenge with Plasmodium yoelii sporozoites conferred sterile protecti

138 CD8+ T cells induced by Plasmodium yoelii sporozoites develop into protective me

139 of AdPyCS also induced high titers of Abs to Plasmodium yoelii sporozoites in mice.

140 s when coadministered with either irradiated Plasmodium yoelii sporozoites or a recombinant adenoviru

141 in-12 (rmIL-12) 2 days before challenge with Plasmodium yoelii sporozoites protects 100% of mice agai

142 Following immunization with Plasmodium yoelii sporozoites, the CD8(+) T cell populat

143 l (NorSpz) and radiation-attenuated (IrrSpz) Plasmodium yoelii sporozoites.

144 prophylactic activity in mice infected with Plasmodium yoelii sporozoites.

145 experimental human malaria vaccines because Plasmodium yoelii SSP2 is the target of protective CD8+

146 fection, some rodent malaria parasites, like Plasmodium yoelii strain 17XNL (Py17XNL), induce a trans

147 ed survival time of Swiss mice infected with Plasmodium yoelii (strain N-67).

148 unization of mice with Plasmodium berghei or Plasmodium yoelii synthetic linear peptide chimeras (LPC

149 y suboptimal treatment of mice infected with Plasmodium yoelii; these mutants exhibited resistance to

150 study, we characterized the MIF homologue of Plasmodium yoelii throughout the life cycle, with emphas

151 on genomes of three apicomplexan pathogens--Plasmodium yoelii, Toxoplasma gondii, and Cryptosporidiu

152 FN-gamma during experimental infections with Plasmodium yoelii, Toxoplasma gondii, and vaccinia virus

153 ere observed for both Plasmodium berghei and Plasmodium yoelii, two different rodent malaria parasite

154 btained when the circumsporozoite protein of Plasmodium yoelii was delivered to DCs.

155 The circumsporozoite protein (PyCSP) of Plasmodium yoelii was engineered into a T. gondii temper

156 Using a model mimicking natural infection by Plasmodium yoelii, we delineated early events governing

157 TLR9(-/-), and MyD88(-/-) mice infected with Plasmodium yoelii, we show that TLR9 and MyD88 regulate

158 us gene pairs from Plasmodium falciparum and Plasmodium yoelii, which likely diverged >or=100 million

159 Previously, we identified a Plasmodium yoelii YM 140-kDa merozoite protein, designat

160 a) in the serum and were resistant to lethal plasmodium yoelii YM infection.

161 d PyPNP, the gene encoding PNP in the lethal Plasmodium yoelii YM strain.

162 -1 (MSP-1) from the rodent malarial parasite Plasmodium yoelii yoelii 17XL, expressed as a fusion pro

163 s identified in the rodent malaria parasites Plasmodium yoelii yoelii and Plasmodium berghei.

164 tigene family in the rodent malaria parasite Plasmodium yoelii yoelii code for 235-kilodalton protein

165 reds of DNA vaccines encoding exons from the Plasmodium yoelii yoelii genomic sequence.

166 of protection in vivo to the rodent parasite Plasmodium yoelii yoelii requires Fc receptor bearing ce

167 oxidative phosphorylation of mitochondria of Plasmodium yoelii yoelii trophozoites were assayed in si

168 hole-genome shotgun sequence of one species, Plasmodium yoelii yoelii, and comparative studies with t

169 gous gene families in both P. falciparum and Plasmodium yoelii yoelii, where no orthologs were predic